Press releases
- Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
- Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
- Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
- Insulet to Present at the Jefferies Global Healthcare Conference
- Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
- Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 279.89 |
---|---|
High | 279.89 |
Low | 279.89 |
Bid | 281.93 |
Offer | 283.02 |
Previous close | 279.89 |
Average volume | -- |
---|---|
Shares outstanding | 70.04m |
Free float | 69.80m |
P/E (TTM) | 61.24 |
Market cap | 13.78bn USD |
EPS (TTM) | 3.21 USD |
Data delayed at least 15 minutes, as of Apr 27 2023.
More ▼